Anti-inflammatory CAR-microglia targeting Aβ for Alzheimer’s disease therapy
By
Xizhong Ding
Xukai Hu
Wanqiang Xue
Yingrui An
Wei Cheng
Shaolong Zhang
Anhua Lei
Jin Zhang
July 14, 2026
Clinical Scorecard: Targeting Aβ with Anti-inflammatory CAR-microglia for the Treatment of Alzheimer’s Disease
At a Glance
Category Detail
Condition Alzheimer’s Disease Key Mechanisms Accumulation of amyloid-β plaques and chronic neuroinflammation leading to neuronal loss. Target Population Patients with Alzheimer’s Disease characterized by Aβ accumulation and neuroinflammation. Care Setting Research and experimental therapeutic development.
Key Highlights
Monoclonal antibodies targeting Aβ show limited efficacy due to neuroinflammatory responses. AXL-CAR microglia demonstrated enhanced Aβ clearance and reduced pro-inflammatory cytokine release. Adoptive transfer of AXL-CAR microglia into AD mouse models resulted in significant reduction of Aβ plaque burden. Guideline-Based Recommendations
Diagnosis
Diagnosis of Alzheimer’s Disease based on clinical criteria and imaging findings. Management
Development of CAR microglia as a therapeutic strategy for enhancing Aβ clearance. Monitoring & Follow-up
Assessment of Aβ levels and neuroinflammatory markers in treated models. Risks
Potential for treatment-associated neuroinflammatory responses. Patient & Prescribing Data
Individuals diagnosed with Alzheimer’s Disease.
CAR microglia targeting Aβ may provide a novel therapeutic approach.
Clinical Best Practices
Utilize TAM receptor signaling to enhance phagocytic clearance of Aβ. Monitor for adverse effects associated with neuroinflammation during treatment. Related Resources & Content
